A Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GDC-0214 conducted in three parts: a single ascending dose study in healthy volunteers, a multiple-ascending dose study in healthy volunteers, and a proof of activity study in patients with mild asthma.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs GDC-0214 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Genentech
- 20 Nov 2018 Planned number of patients changed from 84 to 102.
- 19 Dec 2017 Status changed from not yet recruiting to recruiting.
- 31 Aug 2017 New trial record